Prof Jeanne Tie
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
334 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial
DOI: 10.1001/jamaoncol.2025.61962026
Journal article
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial.
DOI: 10.1093/jnci/djag0652026
Journal article
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer
DOI: 10.1016/S1470-2045(25)00714-42026
Journal article
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers
DOI: 10.1158/1078-0432.CCR-25-21602026
Journal article
A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.
DOI: 10.1200/jco.2026.44.2_suppl.tps2642026
Journal article
BREAKWATER phase 3: Post hoc subgroup analyses by age in patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.2_suppl.1222026
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Colorectal Cancer Through Liquid Biopsy
RECENT SCHOLARLY WORKS
2026
Journal article
Reproducibility and clinical concordance of a tumor-informed MRD assay in patients with resected colorectal cancer from the DYNAMIC trials.
DOI: 10.1200/jco.2026.44.2_suppl.262025
Journal article
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
DOI: 10.1038/s41591-025-04030-w2025
Journal article
Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia
DOI: 10.1007/s40261-025-01489-w2025
Other
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
DOI: 10.1158/1078-0432.30707564